il3-zetakine coupled to a cd33 costimulatory receptor as a dual-targeting car approach in aml
Published 1 year ago • 44 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:42
harnessing t-cells in acute leukemia and an anti-cd33/cd3 bite antibody
-
1:43
cd33-tim3 dual car t-cells enhance specificity of aml treatment
-
7:11
first-in-human cll1-cd33 compound car t-cells for aml
-
2:23
amg 673: novel half-life extended anti-cd33/cd3 bite in r/r aml
-
3:51
novel agents in mzl: btkis, pi3k inhibitors, and immunotherapeutics
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
2:38
flt3 inhibitors: revolutionizing the management of aml
-
2:51
komet-008: a phase i trial of ziftomenib combinations in kmt2a-rearranged or npm1-mutant aml
-
27:30
pancreatic cancer: missed diagnosis and earlier detection
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
21:06
lymphoid series part 1
-
3:17
ziftomenib: mechanism of action and promising results in patients with kmt2ar or npm1m aml
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
2:02
phase ib/iia study of azd4573 and acalabrutinib in patients with r/r dlbcl
-
2:09
heart transplantation in attr amyloidosis
-
2:03
evaluating germline variant gfi1-36n and its impact on dna repair in aml
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
0:41
isct in bringing together the scientific community
-
0:27
cytosmart lux3 fl duo kit - side-by-side fluorescence live-cell imaging
-
4:10
ibrutinib and venetoclax continue to provide benefits for patients with chronic cll and sll
-
0:35
management & outcome of patients with cbf aml and flt3-itd